Adding two blood - borne proteins associated
with cancer cell migration increases the predictive ability of the current biomarker for
pancreatic cancer to detect
early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
«
Pancreatic cancer is a disease
with a poor prognosis, mainly because of the inability to detect the tumor at an
early stage, its high potential for
early dissemination, and its relatively poor sensitivity to chemotherapy or radiation therapy,» according to background information in the article.